Tan Zhen, Xu Jianbo, Li Junfan, You Yating
Department of High Pressure Oxygen, Changde Hospital, Xiangya School of Medicine, Central South University, (The First People's Hospital of Changde City), Changde 415000, Hunan, China.
Department of Medical Equipment, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde 415000, Hunan, China.
Noise Health. 2024;26(123):566-570. doi: 10.4103/nah.nah_103_24. Epub 2024 Dec 30.
In this study, the research team aimed to explore the therapeutic effectiveness of hyperbaric oxygen therapy (HBOT) for noise-induced hearing loss (NIHL), its influence on patient prognosis, and its impact on hearing to provide valuable clinical evidence.
Ninety-four patients with NIHL admitted to The First People's Hospital of Changde City, Hunan, China, from May 2021 to January 2023 were selected for this retrospective analysis. Among them, 43 were given conventional treatment (control group) and 51 were given HBOT (observation group). The clinical efficacy, symptom improvement, and pure-tone hearing thresholds (PTHTs) at different frequencies were detected. All cases were followed up for 12 months to record the NIHL recurrence rates and hearing (hearing threshold), and their quality of life was investigated.
The observation group had higher total effective rate and excellent rate and lower incidence of insomnia, tinnitus, and other symptoms than the control group (P < 0.05). PTHTs were lower in the observation group than in the control group at different frequencies (P < 0.05). Follow-up analysis showed no notable intergroup difference in the NHL recurrence rate (P > 0.05), but the hearing threshold was lower and the quality of life was better in the observation group than in the control group (P < 0.05).
Compared to conventional treatment, HBOT is effective in treating NIHL and can improve the hearing and coagulation function of patients and provide a reliable guarantee for their prognostic health.
本研究中，研究团队旨在探讨高压氧疗法（HBOT）治疗噪声性听力损失（NIHL）的疗效、其对患者预后的影响以及对听力的影响，以提供有价值的临床证据。
选取2021年5月至2023年1月在中国湖南省常德市第一人民医院收治的94例NIHL患者进行这项回顾性分析。其中，43例接受常规治疗（对照组），51例接受高压氧疗法（观察组）。检测临床疗效、症状改善情况以及不同频率的纯音听力阈值（PTHTs）。所有病例随访12个月，记录NIHL复发率和听力（听力阈值），并调查其生活质量。
观察组的总有效率和优良率高于对照组，失眠、耳鸣等症状的发生率低于对照组（P < 0.05）。观察组在不同频率下的PTHTs低于对照组（P < 0.05）。随访分析显示，两组间NHL复发率无显著差异（P > 0.05），但观察组的听力阈值较低，生活质量优于对照组（P < 0.05）。
与常规治疗相比，高压氧疗法在治疗NIHL方面有效，可改善患者的听力和凝血功能，并为其预后健康提供可靠保障。
